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Editorial on the Research Topic
Recent Advances in G Protein-Coupled Receptor Signalling: Impact of Intracellular Location,
Environment and Biased Agonism
G protein-coupled receptors (GPCRs), the largest family of cell surface receptors, are targeted by
approximately 35% of approved drugs that treat a wide variety of diseases including those of the
cardiovascular, respiratory, metabolic, and reproductive systems, and of the central, and
peripheral nervous system. Currently the great majority of approved drugs interact with
orthosteric binding sites on the receptor as agonists, partial agonists, antagonists or inverse
agonists. Of some 800 GPCRs only about 12% have been utilised therapeutically with the
remainder being either olfactory or orphan receptors with many having poorly understood
signalling mechanisms.
Drug development involving GPCRs in the early stages often utilises recombinant systems that
tend to assume that cellular environment has little influence on response. However recent work
suggests that membrane phospholipids, sphingolipids, glycolipids and sterols, and in particular
cholesterol, influence membrane fluidity and GPCR function. Regions of the plasma membrane
that are enriched in combinations of these substituents form microdomains containing not only
receptors but other signalling proteins. The plasma membrane organisation of particular cells can
therefore have a profound effect on GPCR function and regulation. Another paradigm that is being
challenged is that GPCRs are cell surface receptors; many studies now show that GPCRs, their
cognant G-proteins, and second messengers, are present, and functional at a number of
intracellular sites such as the endoplasmic reticulum where they are synthesised, folded, modified,
and assembled but they are also found in nuclear membranes, vesicles, mitochondria, and in the
nucleoplasm.
There continues to be great interest in exploiting novel drug binding sites as identified by allostery,
oligomerisation, and biased agonism as paradigms for novel drug discovery. Allosteric ligands
recognise a topographically distinct site that may be conformationally linked to the orthosteric
binding site. Oligomerisation of GPCRs may create new druggable surfaces that discriminate
oligomerised receptors from monomeric receptors. Biased agonists may interact with the
orthosteric binding site to produce subtly different receptor conformations that differentially affect
signalling pathways. Targeting novel drug binding sites has application for studies of orphan GPCRs,
for known target receptors where selectivity has not been achieved by conventional approaches, and for
receptor targets currently exploited therapeutically but where side effects are a significant problem.
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These new paradigms are altering approaches to drug
development, and have the potential to produce more
efficacious drugs with novel modes of action, and reduced
unwanted effects.
The studies described in this issue explore many of these
concepts. In “Fine tuning muscarinic acetylcholine receptor
signalling through allostery and bias”, van der Westhuizen
et al. provide an excellent example of known drug targets, the
M1 and M4 muscarinic acetylcholine (mACh) receptors, that
have been difficult to target selectively using the orthosteric
ligand binding site for acetylcholine that is well conserved
across mACh receptor subtypes. Their findings suggest that in
addition to an allosteric mode of action, drug candidates may
have to exhibit a particular bias profile in order to display
therapeutic efficacy while minimising on-target side effects.
The concept is continued in two studies that examine the
utility of allosteric agonists at the Follicle Stimulating Hormone
(FSH) receptor. In “Pharmacological programming of endosomal
signaling activated by small molecule ligands of the follicle
stimulating hormone receptor”, Sposini et al. examine the
properties of two low MWt allosteric agonists of the FSH
receptor and show that the compounds possessed different
abilities to alter receptor endosomal trafficking and cAMP
signalling suggesting that these functions can be selected for
pharmacologically. In “Discovery and preclinical development of
orally active small molecules that exhibit highly selective follicle
stimulating hormone receptor agonism”, Nataraja et al. describe the
development of orally active FSH receptor allosteric agonists with
clinical potential for the treatment of infertility. They show that these
compounds mimic the biological activity of recombinant human
FSH in preclinical studies, and cause folliculogenesis, and
superovulation in rats, and mice. Importantly, the compounds
have properties that make them suitable for oral administration,
that would avoid the current limitation in the clinic of using
recombinant FSH that has to be injected.
The concept of biased agonism is explored in “The G protein
biased smallmolecule apelin agonist CMF-019 is diseasemodifying
in endothelial cell apoptosis in vitro and induces vasodilatation
without desensitisation in vivo” by Read et al. that describes a study
on the apelin receptor, a target for the treatment of pulmonary
arterial hypertension. The endogenous peptide agonists are
unsuitable therapeutics due to poor bioavailability, rapid
desensitisation, and rapid inactivation. In contrast, the small
molecule agonist CMF-019 not only retains the vasodilator
properties of the peptides without receptor desensitisation but
protects endothelial cells from apoptosis. Such biased agonism
could form the basis for new therapeutic agents. The study on
“The effect of cell surface expression and linker sequence on
the recruitment of arrestin to the GIP receptor”, by Al-Sabah
et al. examines one of the problems associated with the
demonstration of bias, that is the choice, and configuration of
the assays used. They show that replacement of the native signal
peptide in the GIP receptor with a HA signal peptide influences the
experimental result probably by increasing receptor cell surface
expression. The linker between the receptor and fluorescent
protein was also shown to be important and could result in the
inclusion of phosphorylation sites that produced false positive
results. In another study that points to the care that must be
FIGURE 1 | Factors affecting signalling in response to activation of GPCRs. Glycolipids (blue hexagons), phospholipids (green rectangles), and sterols (yellow) can
influence ligand binding at orthosteric, and allosteric sites. Ligands can produce different receptor conformations leading to different signalling patterns and degrees of
interaction with β-arrestins, internalisation, and desensitisation. Ligands with differing physicochemical properties can result in altered spatial and temporal signal
integration, and affect the relative degree of cell surface/intracellular signal transduction as well as influencing receptor recycling or lysosomal degradation.
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exercised with the use of tool compounds to examine GPCR
signalling, Chen and Sabatini caution on “The kinase specificity
of protein kinase inhibitor peptide (PKI)” showing in a study of 55
mouse kinases that in addition to inhibition of PKA, PKI also
can activate multiple isoforms of PKC. This may suggest re-
evaluation of some studies using PKI as a specific inhibitor
of PKA.
In “G protein-coupled receptors in taste physiology and
pharmacology” Ahmad and Dalziel examine the interesting
properties of GPCR taste receptors that not only respond to
a wide variety of ligands including orthosteric agonists, and
antagonists but also positive, and negative allosteric modulators.
While initially identified as taste receptors, it is now recognised
that these receptors control other physiological processes in
addition to taste, with expression of mRNA, and receptor
protein identified in range of tissues in humans (Human
Protein Atlas https://www.proteinatlas.org/). They outline the
value of potential structural studies but emphasise the
challenges associated with these studies and taste receptors
and indicate how these may be overcome. The paper by
Mouat et al. “Deletion of orphan G protein-coupled receptor
GPR37L1 in mice alters cardiovascular homeostasis in a sex-
specific manner” provides more evidence that the orphan GPCR
GPR37L1 is involved in maintaining sympathetic vasomotor
tone. The authors were also able to demonstrate gender
differences between responses with female GPR37L1-/- mice
showing an attenuation of cardiovascular reactivity to aversive
but not appetitive stimuli. The study draws attention to gender
differences in physiological responses and how these can affect
drug action. Substantial progress has been made in
understanding the physiological role of GPR37L1 by using
gene deletion and identifying a potential drug target without
knowing the identity of the endogenous ligand. The strategy
described has wider applicability to the remaining orphan
GPCRs that have not yet been exploited.
In their paper “Inhibition of the proliferation of human lung
fibroblasts by prostacyclin receptor agonists is linked to a sustained
cAMP signal in the nucleus” Roberts et al. (2021), examine factors
underlying the anti-fibrotic effects of GPCR agonists acting to
increase cAMP. They show that the anti-fibrotic effects of a Gαs-
coupled prostacyclin receptor requires sustained increases in
cAMP in the nucleus to inhibit PDGF driven nuclear ERK1/2
and fibroblast proliferation indicating that both location and
duration of the signal are key factors.
The studies included in this themed issue describe some of the
concepts influencing current GPCR research with approaches
such as the targeting of allosteric sites and development of biased
agonists likely to produce new therapeutics that either act at
known targets with fewer side effects or at targets for which there
are no drugs currently available. Some studies also point to
deficiencies in current assay tools that can be used to improve
drug development.
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